About us

A word from our CEO Hanna Sjöström

Our mission is to give preterm born infants a better start in life. By providing neonatal intensive care units (NICUs) with a groundbreaking innovation for continuous lung monitoring that also can provide immediately alert to the personnel of serious health complications, we are upgrading the care that these fragile patients currently receive and filling a unique market gap for pediatric medical devices.

Kind regards,

Hanna Sjöström

CEO, Neola Medical AB

Email: Hanna.Sjostrom@neolamedical.com

Hanna Sjöström

Hanna Sjöström

CEO

Board & Management

Neola Medical’s Board consists of five members elected at Neola Medical’s Annual General Meeting on May 19, 2022.

Märta Lewander Xu

Chairman of the Board since 2019, former CEO on a part-time basis and board member for Neola Medical 2016-2019.

Experience and education

Märta Lewander Xu has a doctorate in technology in physics, has a master’s degree in technical physics and a teaching degree in mathematics and physics. Märta was employed at Gasporox AB (publ) in 2010 as CTO and has been CEO of Gasporox AB (publ) since January 2015, which is listed on Nasdaq First North, board member of Lund Laser Center at Lund University, BeammWave AB, Serstech AB and Inscientia AB, and deputy board member of CxTx AB.

Märta Lewander Xu is independent in relation to the company and its management, independent in relation to the company’s major owners.

Number of shares held in the company

244,316 shares, 60,000 warrants issued within the framework of incentive program 2021/2025B.

 

Anders Weilandt

Board member since 2022.

Experience and education

Anders Weilandt, born 1961, is a Medical Electronics Engineer and holds an Executive MBA from Copenhagen Business School. Anders is the CEO of Chordate Medical AB (publ) and currently has a number of board assignments in various companies. He has previously been President of Ascendia MedTech AB, President of Diabetes Tools Sweden AB and Board member and CEO of Stille AB (publ). Anders has extensive experience of regulatory processes, CE marking and international expansion of new medical devices.

Anders Weilandt is independent in relation to the company and its management, dependent in relation to the company’s major owners.

Number of shares held in the company

0 shares.

Tommy Hedberg

Board member since 2022.

Experience and education

Tommy Hedberg, born 1955, has a Chemical Engineering degree followed by a post-secondary Economics degree. Tommy also has a medical LIF undergraduate degree from his time at Janssen Pharma. During the years 1998 – 2014, Tommy was CEO 2014–2016 and a board member at Atos Medical. He was also responsible for marketing and sales at Atos Medical 1990 – 1998. Before Tommy started working at Atos Medical, he worked as head of the medical technology division at Medscand with international marketing and sales. Prior to that, Tommy worked for 9 years in sales and marketing at Janssen Pharma.

Tommy Hedberg is independent in relation to the company and its management, independent in relation to the company’s major owners.

Number of shares held in the company

0 shares.

Mattias Lundin

Board member since 2022.

Experience and education

Mattias Lundin, born 1968, has a degree in Business Administration from IHM Business School in Stockholm and several international strategy and leadership training courses within the Sara Lee Corporation, the Getinge Group and IMD Lausanne. He now works as CEO of Lumito AB (publ) and has previously been Vice President Global Sales at CellaVision AB (publ) and held a number of senior positions within the Arjo Group (formerly Getinge), most recently as Vice President Commercial for International Mature Markets. Mattias has solid international experience in sales and marketing and is a team player with a strong track record when it comes to building successful teams for global expansion of new technology.

Mattias Lundin is independent in relation to the company and its management, independent in relation to the company’s major owners.

Number of shares held in the company

0 shares.

 

Urban Ottosson

Board member since 2021.

Experience and education

Urban Ottosson has a master’s degree in economics from Lund University and a degree from KTH Executive School in Stockholm. He has worked as CFO since 1999 in several companies, including HEXPOL, Beijer Electronics, Höganäs Group, Öresundskraft and Lammhults Design Group. He is also a private investor in addition to his assignments. Former board member of Lendify AB and chairman of the board of Modity Energy Trading. He was CFO of Neola Medical 2020-2021. He is the CEO and board member of Predictus Asset Management AB, and CFO of TePe Munhygienprodukter.

Urban Ottosson is independent in relation to the company and its management, independent in relation to the company’s major owners.

Number of shares held in the company

156,250 shares via Predictus Asset Management AB, 100,000 warrants issued within the framework of the Incentive Program 2021/2025A.

Neola Medical management & team

Neola Medical’s management consists of CEO Hanna Sjöström and CFO Christian Gyllenberg. In addition to the management, there is a strong team of key people with both technical and medical expertise. The team is also complemented by an extensive network of specialist consultants.

Hanna Sjöström

External CEO since 2019.

Experience and education

Hanna Sjöström has a master’s degree in economics from Lund University (Master of Business Administration) with a specialization in Technology Management. She has also taken a course in leadership in the Executive MBA program of the Swedish Management Group, and is a certified board member in Life Sciences. Hanna has held leading positions in large groups such as L’Oréal, the Coca-Cola Company and a senior position at TePe Munhygiensproduker AB, where she was part of the company’s management team. Hanna is also chairman of the board of Inscientia AB.

Number of shares held in the company

265,276 shares, 200,000 warrants issued within the framework of the Incentive Program 2021/2025A.

Christian Gyllenberg

CFO since 2022.

Experience and education

Christian Gyllenberg has a bachelor’s degree in Business Law and a bachelor’s degree in Business Administration from Kristianstad University. He has previously worked with auditing and as a Business Controller in business-related roles at companies in various industries such as EY, Attendo and DHL. He is the CFO of Aurora Punks alongside his assignment at Neola Medical.

Number of shares held in the company

0 shares.

Addressing a critical medical need

Every year almost 15 million children are born preterm (before 37 weeks of pregnancy). Many of them require intensive care. Many people know someone who was born preterm or has been affected by a preterm birth, but fewer understand the risks that arise from it. One of many challenges preterm born infants face is underdeveloped lungs that are unable to provide oxygen to the blood, resulting in a life-threatening condition that, if survived, can lead to complications later on in life.

Neola Medical’s technological innovation Neola® can help healthcare personnel make more informed decisions based on real-time information. Neola Medical’s proven technology uses laser spectroscopy to continuously measure lung volume changes and oxygen gas concentration in preterm infants. This is a safe and non-invasive method to monitor the lungs of these vulnerable patients in real time, thereby provide the possibility of instant treatment of life-threatening conditions and decreasing the risk of disabilities later in life.

Neola® has the potential to provide better care, fewer days in intensive care and healthier lives for preterm born infants.

Building on a historic Swedish legacy of medical technology innovation

Sweden has made invaluable contributions to global healthcare, specifically in neonatal intensive care. As a result, the survival rate of preterm born infants has increased to almost 90 percent. Such was not the case in the 1970s, when modern neonatal care was first introduced. At that time, the mortality rate of children weighing under one kilo was over 90 percent. Since then, Sweden has helped develop world class neonatal intensive care, built on a foundation of the latest technology and nurturing methods that involve parents as well.

Following in the footsteps of diagnostic ultrasound, which was developed in Lund, Sweden in the 1950’s, Lund-based medical technology innovation once again has the potential to revolutionize health care the world over.

Neola Medical Headquarters

Founded in 2016 and headquartered in Lund, Sweden, Neola Medical is building on a historic Swedish legacy of medical technology innovation and invaluable contributions to global health care. Neola Medical’s employees, management and board have a wide-ranging, specific and very competitive knowledge of product development, user needs and commercialization of medical technology, making the company well-positioned to take Neola® to market.

For Investors

We are on a journey to revolutionize neonatal intensive care
Learn more about investing in Neola Medical